Virpi Talman

TL;DR: Current knowledge of the mechanisms of both reparative and reactive cardiac fibrosis in response to myocardial infarction are summarized, the potential of inducing cardiac regeneration through direct reprogramming of fibroblast and myofibroblasts into cardiomyocytes are discussed, and the currently available and potential future therapeutic strategies to inhibit cardiac Fibrosis are reviewed.

TL;DR: The known mediators of the bidirectional CM-EC interactions are summarized and related recent advances in the development of therapies aiming to promote heart repair and regeneration targeting these two cell types are discussed.

TL;DR: In vivo single-photon emission computed tomography and autoradiography demonstrate increased accumulation of ANP-PSi nanoparticles in the ischemic heart, particularly in the endocardial layer of the left ventricle, demonstrating cardioprotective potential.

TL;DR: A spermine‐acetalated dextran‐based functional nanoparticle is developed for pH‐triggered drug delivery of two poorly water soluble small molecules capable of increasing the efficiency of direct reprogramming of fibroblast into cardiomyocytes and thus, potential cardiac regeneration therapy.

TL;DR: This study is the first systems‐level resource combining data from genomewide transcriptomics with global quantitative proteomics and untargeted metabolomics analyses in the mouse heart throughout the early postnatal period, providing evidence that the mevalonate and ketogenesis routes may participate in regulating the cardiomyocyte cell cycle.